The role of ELOVL1 in very long-chain fatty acid homeostasis and X-linked adrenoleukodystrophy
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
X-linked adrenoleukodystrophy (X-ALD) is caused by mutations in the ABCD1 gene encoding the peroxisomal ABC transporter adrenoleukodystrophy protein (ALDP). X-ALD is characterized by the accumulation of very long-chain fatty acids (VLCFA; > or =C24) in plasma and tissues. In this manuscript we provide insight into the pathway underlying the elevated levels of C26:0 in X-ALD. ALDP transports VLCFacyl-CoA across the peroxisomal membrane. A deficiency in ALDP impairs peroxisomal beta-oxidation of VLCFA but also raises cytosolic levels of VLCFacyl-CoA which are substrate for further elongation. We identify ELOVL1 (elongation of very-long-chain-fatty acids) as the single elongase catalysing the synthesis of both saturated VLCFA (C26:0) and mono-unsaturated VLCFA (C26:1). ELOVL1 expression is not increased in X-ALD fibroblasts suggesting that increased levels of C26:0 result from increased substrate availability due to the primary deficiency in ALDP. Importantly, ELOVL1 knockdown reduces elongation of C22:0 to C26:0 and lowers C26:0 levels in X-ALD fibroblasts. Given the likely pathogenic effects of high C26:0 levels, our findings highlight the potential of modulating ELOVL1 activity in the treatment of X-ALD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“ALDP deficiency in X-ALD has two major effects: 1) it impairs peroxisomal VLCFA beta-oxidation and 2) it raises cytosolic VLCFacyl-CoA levels [50].”
From X-linked adrenoleukodystrophy: Clinical, metabolic, genetic and pathophysiological aspects (2012) · cites this paper as [50]
The cited source says what the claim attributes to it.
In the citing paper
“The synthesis of VLCFA (C26:0) is enhanced in X-ALD [56] and it requires the elongases ELOVL6 and ELOVL1 [50,51].”
From X-linked adrenoleukodystrophy: Clinical, metabolic, genetic and pathophysiological aspects (2012) · cites this paper as [50]
In the citing paper
“It was recently demonstrated that the synthesis of C24:0 and C26:0 is carried out by the concerted action of ELOVL6 (C18:0-C22:0) and ELOVL1 (C24:0-C26:0) [50] (Fig. 2).”
From X-linked adrenoleukodystrophy: Clinical, metabolic, genetic and pathophysiological aspects (2012) · cites this paper as [50]
In the citing paper
“These data establish that ALDP transports VLCFacyl-CoA into peroxisomes”
From X-linked adrenoleukodystrophy: Clinical, metabolic, genetic and pathophysiological aspects (2012) · cites this paper as [50]
In the citing paper
“Importantly, ELOVL1 knockdown reduces elongation of C22:0 to C26:0 and lowers C26:0 levels in X-ALD fibroblasts [50].”
From X-linked adrenoleukodystrophy: Clinical, metabolic, genetic and pathophysiological aspects (2012) · cites this paper as [50]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Metabolic and Molecular Bases of Inherited Disease
Scriver, R. C. (1995) · Medical Entomology and Zoology · Cited by 12,101
The metabolic and molecular bases of inherited disease
Chen, Y.-T. (2001) · Medical Entomology and Zoology · Cited by 6,928
Hematopoietic Stem Cell Gene Therapy with a Lentiviral Vector in X-Linked Adrenoleukodystrophy
Cartier, N., Hacein-Bey-Abina, S., Bartholomae, C. C., Veres, G., Schmidt, M., Kutschera, I., Vidaud, M., Abel, U., Dal-Cortivo, L., Caccavelli, L., et al. (2009) · Science · doi:10.1126/science.1171242 · Cited by 1,508 · cited 5×
“The recent breakthrough in gene therapy is currently only applied to CCALD (Cartier et al, 2009).”
BackgroundInfluentialPutative X-linked adrenoleukodystrophy gene shares unexpected homology with ABC transporters
Mosser, J., Douar, A.-M., Sarde, C.-O., Kioschis, P., Feil, R., Moser, H., Poustka, A.-M., Mandel, J.-L., & Aubourg, P. (1993) · Nature · doi:10.1038/361726a0 · Cited by 1,202 · cited 2×
“90 The role of ELOVL1 in very long-chain fatty acid homeostasis and X-linked adrenoleukodystrophy”
BackgroundFatty acid elongases in mammals: their regulation and roles in metabolism
JAKOBSSON, A., WESTERBERG, R., & JACOBSSON, A. (2006) · Progress in Lipid Research · doi:10.1016/j.plipres.2006.01.004 · Cited by 936 · cited 2×
“90 The role of ELOVL1 in very long-chain fatty acid homeostasis and X-linked adrenoleukodystrophy”
BackgroundMoser, H. W., Mahmood, A., & Raymond, G. V. (2007) · Nature Clinical Practice Neurology · doi:10.1038/ncpneuro0421 · Cited by 663
Elongation of long-chain fatty acids
Leonard, A. E., Pereira, S. L., Sprecher, H., & Huang, Y.-S. (2004) · Progress in Lipid Research · doi:10.1016/s0163-7827(03)00040-7 · Cited by 584 · cited 2×
“90 The role of ELOVL1 in very long-chain fatty acid homeostasis and X-linked adrenoleukodystrophy”
BackgroundOh, C.-S., Toke, D. A., Mandala, S., & Martin, C. E. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.28.17376 · Cited by 486 · cited 3×
“90 The role of ELOVL1 in very long-chain fatty acid homeostasis and X-linked adrenoleukodystrophy”
BackgroundZhang, K., Kniazeva, M., Han, M., Li, W., Yu, Z., Yang, Z., Li, Y., Metzker, M. L., Allikmets, R., Zack, D. J., et al. (2001) · Nature Genetics · doi:10.1038/83817 · Cited by 453 · cited 2×
“It is expressed predominantly in retina, brain and sperm (Tvrdik et al, 2000; Vasireddy et al, 2007; Zhang et al, 2001).”
BackgroundPeters, C., Charnas, L. R., Tan, Y., Ziegler, R. S., Shapiro, E. G., DeFor, T., Grewal, S. S., Orchard, P. J., Abel, S. L., Goldman, A. I., et al. (2004) · Blood · doi:10.1182/blood-2003-10-3402 · Cited by 374 · cited 2×
“90 The role of ELOVL1 in very long-chain fatty acid homeostasis and X-linked adrenoleukodystrophy”
Background
Research works printed but not linked: 1
- Moser AB,Kreiter N,Bezman L,Lu S,Raymond GV,Naidu S,Moser HW(1999)Plasma very long chain fatty acids in 3,000 peroxisome disease patients and 29,000 controls.Ann Neurol45:100‐110 · doi:10.1002/1531-8249(199901)45:1<100::aid-art16>3.0.co;2-u
Cited by
Engelen, M., Kemp, S., de Visser, M., van Geel, B. M., Wanders, R. J., Aubourg, P., & Poll-The, B. (2012) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-7-51 · Cited by 562
“ELOVL1 expression is not increased in X-ALD fibroblasts, but increased synthesis of VLCFA is due to increased substrate availability [6].”
InfluentialSelf-citationHuman disorders of peroxisome metabolism and biogenesis
Waterham, H. R., Ferdinandusse, S., & Wanders, R. J. A. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2015.11.015 · Cited by 368
Self-citationX-linked adrenoleukodystrophy: Clinical, metabolic, genetic and pathophysiological aspects
Kemp, S., Berger, J., & Aubourg, P. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2012.03.012 · Cited by 283
“The synthesis of VLCFA (C26:0) is enhanced in X-ALD [56] and it requires the elongases ELOVL6 and ELOVL1 [50,51].”
InfluentialSelf-citationMetabolism of Very Long-Chain Fatty Acids: Genes and Pathophysiology
Sassa, T., & Kihara, A. (2014) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2014.017 · Cited by 302
“As mentioned earlier, ELOVL1 is responsible for the synthesis of saturated and monounsaturated C24-C26 VLCFAs such as those accumulated in X-ALD.”
InfluentialAdrenoleukodystrophy—Neuroendocrine pathogenesis and redefinition of natural history
Kemp, S., Huffnagel, I. C., Linthorst, G. E., Wanders, R. J., & Engelen, M. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.90 · Cited by 275
Self-citationKihara, A. (2016) · Progress in Lipid Research · doi:10.1016/j.plipres.2016.04.001 · Cited by 237
Pathophysiology of X-linked adrenoleukodystrophy
Berger, J., Forss-Petter, S., & Eichler, F. S. (2014) · Biochimie · doi:10.1016/j.biochi.2013.11.023 · Cited by 238
“As the majority of VLCFA are derived from endogenous synthesis, the enzymes involved in this pathway such as the elongases of very long-chain fatty acids, ELOVL6 or ELOVL1, are other candidates [71,72].”
BackgroundX-linked adrenoleukodystrophy in women: A cross-sectional cohort study
Engelen, M., Barbier, M., Dijkstra, I. M. E., Schür, R., de Bie, R. M. A., Verhamme, C., Dijkgraaf, M. G. W., Aubourg, P. A., Wanders, R. J. A., van Geel, B. M., et al. (2014) · Brain · doi:10.1093/brain/awt361 · Cited by 234
Self-citationMetabolic functions of peroxisomes in health and disease
Wanders, R. J. A. (2014) · Biochimie · doi:10.1016/j.biochi.2013.08.022 · Cited by 232
Self-citationFatty acid omega‐oxidation as a rescue pathway for fatty acid oxidation disorders in humans
Wanders, R. J. A., Komen, J., & Kemp, S. (2011) · The FEBS Journal · doi:10.1111/j.1742-4658.2010.07947.x · Cited by 218
Self-citationTurk, B. R., Theda, C., Fatemi, A., & Moser, A. B. (2020) · International Journal of Developmental Neuroscience · doi:10.1002/jdn.10003 · Cited by 210
“There are 7 ELOVL enzymes; however, ELOVL1, is the one responsible for the chain elongation of VLCFA (Ofman et al., 2010; Ohno et al., 2010).”
BackgroundGouw, A. M., Margulis, K., Liu, N. S., Raman, S. J., Mancuso, A., Toal, G. G., Tong, L., Mosley, A., Hsieh, A. L., Sullivan, D. K., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.07.012 · Cited by 200
“Consistent with this idea, MYC induced mRNA expression of the FA elongases ELOVL2 and ELOVL6, which add two carbons to FA chains (Moon et al., 2014; Ofman et al., 2010; Pauter et al., 2014) (Figure 6D).”
BackgroundPeroxisomes in brain development and function
Berger, J., Dorninger, F., Forss-Petter, S., & Kunze, M. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2015.12.005 · Cited by 194
“elongation of very long-chain fatty acids 1 (ELOVL1), in the homeostasis of VLCFA in X-ALD [116,117].”
BackgroundX-Linked Adrenoleukodystrophy: Pathogenesis and Treatment
Engelen, M., Kemp, S., & Poll-The, B.-T. (2014) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-014-0486-0 · Cited by 187
Self-citationPeroxisomal ABC transporters: Structure, function and role in disease
Morita, M., & Imanaka, T. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2012.02.009 · Cited by 183
“In addition, no decrease in the C24:0 β-oxidation activity was observed by the silencing ABCD3 in ABCD1-knockdown U87 cells (manuscript in preparation), suggesting that the contribution of ABCD3 to peroxisomal VLCFA β-oxidation might be negligible.”
BackgroundInfluentialRetinal very long-chain PUFAs: new insights from studies on ELOVL4 protein
Agbaga, M.-P., Mandal, M. N. A., & Anderson, R. E. (2010) · Journal of Lipid Research · doi:10.1194/jlr.r005025 · Cited by 167
Sassa, T., Ohno, Y., Suzuki, S., Nomura, T., Nishioka, C., Kashiwagi, T., Hirayama, T., Akiyama, M., Taguchi, R., Shimizu, H., et al. (2013) · Molecular and Cellular Biology · doi:10.1128/mcb.00192-13 · Cited by 166
“Knockdown of ELOVL1 in X-ALD fibroblasts reduces the elongation of C22:0-CoA to C26:0-CoA and lowers cellular C26:0 levels (30).”
BackgroundFatty acid metabolism in the progression and resolution of CNS disorders
Bogie, J. F. J., Haidar, M., Kooij, G., & Hendriks, J. J. A. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.01.004 · Cited by 167
Marquez, B., & Van Bambeke, F. (2011) · Current Drug Targets · doi:10.2174/138945011795378504 · Cited by 165
Wiesinger, C., Kunze, M., Regelsberger, G., Forss-Petter, S., & Berger, J. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.445445 · Cited by 145
“Thus, differentmechanisms, such as fatty acid elongation and -oxidation, must be considered as the explanation for the lack of C22:0 accumulation in X-ALD fibroblasts as well as in patients (3, 37, 38).”
BackgroundBerger, J., Wiesinger, C., & Eichler, F. (2015) · The Application of Clinical Genetics · doi:10.2147/tacg.s49590 · Cited by 140
Differential substrate specificities of human ABCD1 and ABCD2 in peroxisomal fatty acid β-oxidation
van Roermund, C. W. T., Visser, W. F., IJlst, L., Waterham, H. R., & Wanders, R. J. A. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2010.11.010 · Cited by 128
Self-citationBaarine, M., Andreoletti, P., Athias, A., Nury, T., Zarrouk, A., Ragot, K., Véjux, A., Riedinger, J., Kattan, Z., Bessède, G., et al. (2012) · Neuroscience · doi:10.1016/j.neuroscience.2012.03.058 · Cited by 127
“As ELOVL1 has been reported as the single enzyme catalyzing the synthesis of both saturated VLCFA (C26:0) and monounsaturated VLCFA (C26:1), this enzyme provides new insights on the pathways leading to elevated levels of VLCFA in X-ALD (Ofman et al., 2010).”
Biochemical aspects of X-linked adrenoleukodystrophy
Kemp, S., & Wanders, R. (2010) · Brain Pathology · doi:10.1111/j.1750-3639.2010.00391.x · Cited by 116
“More recently, we demonstrated using fibroblasts from X-ALD patients and controls that a deficiency of ALDP impairs peroxisomal b-oxidation of VLCFA but also raises cytosolic levels of VLCFacyl-CoA (54).”
BackgroundInfluentialSelf-citationKemp, S., Theodoulou, F. L., & Wanders, R. J. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01435.x · Cited by 115
“These VLCFacyl-CoA esters are substrate for further elongation to even longer fatty acids by ELOVL1, the human C26 specific elongase (Kemp and Wanders, 2010; Ofman et al., 2010).”
BackgroundSelf-citationInduced pluripotent stem cell models from X-linked adrenoleukodystrophy patients
Jang, J., Kang, H., Kim, H., Kim, J. Y., Huh, Y. J., Kim, D., Yoo, J., Lee, J., Lim, B., Lee, J., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22486 · Cited by 109
“This is in line with the finding of Ofman et al that ELOVL1 expression in CCALD fibroblasts was lower than that of control (WT fibroblast).(31) Unexpectedly, ELOVL1 level in AMN oligodendrocytes was slightly higher than that of CCALD oligodendrocytes, whereas ABCD2 in CCALD oligodendrocytes was slightly higher than th…”
ResultA role for the human peroxisomal half-transporter ABCD3 in the oxidation of dicarboxylic acids
van Roermund, C. W. T., IJlst, L., Wagemans, T., Wanders, R. J. A., & Waterham, H. R. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2013.12.001 · Cited by 101
Self-citationFatty Acid Elongase 7 Catalyzes Lipidome Remodeling Essential for Human Cytomegalovirus Replication
Purdy, J. G., Shenk, T., & Rabinowitz, J. D. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.02.003 · Cited by 103
Sassa, T., Suto, S., Okayasu, Y., & Kihara, A. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2012.04.008 · Cited by 102
Effects of environmentally relevant metformin exposure on Japanese medaka (Oryzias latipes)
Ussery, E. J., Bridges, K. N., Pandelides, Z., Kirkwood, A. E., Bonetta, D. T., Venables, B. J., Guchardi, J., & Holdway, D. A. (2018) · Aquatic Toxicology · doi:10.1016/j.aquatox.2018.10.003 · Cited by 71
How the brain fights fatty acids’ toxicity
Schönfeld, P., & Reiser, G. (2021) · Neurochemistry International · doi:10.1016/j.neuint.2021.105050 · Cited by 78
Sassa, T., Wakashima, T., Ohno, Y., & Kihara, A. (2014) · Journal of Lipid Research · doi:10.1194/jlr.m044586 · Cited by 69
“Knockdown of ELOVL1 in X-ALD fibroblasts is reported to lower the level of C26:0 (21), suggesting ELOVL1 as a potential pharmacological target for the treatment of X-ALD (17, 21, 22).”
BackgroundPeroxisomal ABC Transporters: An Update
Tawbeh, A., Gondcaille, C., Trompier, D., & Savary, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22116093 · Cited by 68
“This accumulation results from the impossibility of their entry into the peroxisome for their degradation by β-oxidation, but also from an increased endogenous biosynthesis [87].”
BackgroundTreatment of cerebral adrenoleukodystrophy: allogeneic transplantation and lentiviral gene therapy
Gupta, A. O., Raymond, G., Pierpont, E. I., Kemp, S., McIvor, R. S., Rayannavar, A., Miller, B., Lund, T. C., & Orchard, P. J. (2022) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2022.2124857 · Cited by 67
“concentrations of saturated VLCFA >C22:0 are observed [5,6].”
BackgroundSelf-citationWanders, R. J. A., Vaz, F. M., Waterham, H. R., & Ferdinandusse, S. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-60204-8_5 · Cited by 86
Self-citationWeber, F. D., Wiesinger, C., Forss-Petter, S., Regelsberger, G., Einwich, A., Weber, W. H. A., Kohler, W., Stockinger, H., & Berger, J. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddt645 · Cited by 63
“They can be further elongated by enzymes of the ELOVL (elongation of VLCFAs) family and may be incorporated into different lipids such as phosphatidylcholine, gangliosides or sulphatides and lipoproteins (9).”
BackgroundLaunay, N., Ruiz, M., Grau, L., Ortega, F. J., Ilieva, E. V., Martínez, J. J., Galea, E., Ferrer, I., Knecht, E., Pujol, A., et al. (2017) · Acta Neuropathologica · doi:10.1007/s00401-016-1655-9 · Cited by 62
“In addition, VLCFA are elongated from C16:0 in the ER [50, 68], and subsequently imported by ABCD1 and ABCD2 transporters into peroxisomes for degradation via β-oxidation [30, 93].”
BackgroundPeroxisomal Metabolite and Cofactor Transport in Humans
Chornyi, S., IJlst, L., van Roermund, C. W. T., Wanders, R. J. A., & Waterham, H. R. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.613892 · Cited by 74
Self-citationPark, Y.-H., Jang, W.-H., Seo, J. A., Park, M., Lee, T. R., Park, Y.-H., Kim, D. K., & Lim, K. (2011) · Journal of Investigative Dermatology · doi:10.1038/jid.2011.333 · Cited by 68
Abe, Y., Honsho, M., Nakanishi, H., Taguchi, R., & Fujiki, Y. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2014.01.001 · Cited by 61
ELOVL4 protein preferentially elongates 20:5n3 to very long chain PUFAs over 20:4n6 and 22:6n3
Yu, M., Benham, A., Logan, S., Brush, R. S., Mandal, M. N. A., Anderson, R. E., & Agbaga, M.-P. (2012) · Journal of Lipid Research · doi:10.1194/jlr.m021386 · Cited by 57
Kutkowska‐Kaźmierczak, A., Rydzanicz, M., Chlebowski, A., Kłosowska-Kosicka, K., Mika, A., Gruchota, J., Jurkiewicz, E., Kowaléwski, C., Pollak, A., Stradomska, T. J., et al. (2018) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2017-105172 · Cited by 63
Lipids in the Physiopathology of Hereditary Spastic Paraplegias
Darios, F. D., Mochel, F., & Stévanin, G. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00074 · Cited by 57
Pizcueta, P. M., Vergara, C., Emanuele, M., Vilalta, A., Rodríguez‐Pascau, L., & Martinell, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043201 · Cited by 59
Raas, Q., Gondcaille, C., Hamon, Y., Leoni, V., Caccia, C., Ménétrier, F., Lizard, G., Trompier, D., & Savary, S. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2019.02.006 · Cited by 53
Engelen, M., Schackmann, M. J. A., Ofman, R., Sanders, R., Dijkstra, I. M. E., Houten, S. M., Fourcade, S., Pujol, A., Poll‐The, B. T., Wanders, R. J. A., et al. (2012) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-012-9471-4 · Cited by 48
“We used purified microsomes from wild type and ELOVL1 over-expressing mice to test the effect of BF on elongation of both long-chain fatty acids (LCFA) and VLCFA.”
BackgroundInfluentialSelf-citationBaarine, M., Beeson, C., Singh, A. K., & Singh, I. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.12992 · Cited by 52
“Elongation of very long chain fatty acids (ELOVL) 1 and 3 have chain length specificity toward VLCFA (Westerberg et al. 2004; Ofman et al. 2010; Ohno et al. 2010) and are therefore likely to play a role in the pathophysiology of X-ALD.”
C26:0-Carnitine Is a New Biomarker for X-Linked Adrenoleukodystrophy in Mice and Man
van de Beek, M.-C., Dijkstra, I. M. E., van Lenthe, H., Ofman, R., Goldhaber-Pasillas, D., Schauer, N., Schackmann, M., Engelen-Lee, J.-Y., Vaz, F. M., Kulik, W., et al. (2016) · PLOS ONE · doi:10.1371/journal.pone.0154597 · Cited by 48
“In contrast, microsomes from CMV-ELOVL1 mice had a 25-fold higher elongation activity for C22:0-CoA, which is in agreement with the substrate specificity of ELOVL1 [24, 32].”
BackgroundMethodResultSelf-citationA review on neuropharmacological role of erucic acid: an omega-9 fatty acid from edible oils
Kumar, J. B. S., & Sharma, B. (2020) · Nutritional Neuroscience · doi:10.1080/1028415x.2020.1831262 · Cited by 54
“It is used along with oleic acid in 4:1 ratio for the dietary treatment of XALD, however the exact mechanism by which it prevents the accumulation of VLCFAs is not yet identified.”
BackgroundInfluentialLipid-induced endoplasmic reticulum stress in X-linked adrenoleukodystrophy
van de Beek, M.-C., Ofman, R., Dijkstra, I. M. E., Wijburg, F. A., Engelen, M., Wanders, R. J. A., & Kemp, S. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2017.06.003 · Cited by 54
Self-citationBhandari, S., Lee, J. N., Kim, Y.-I., Nam, I.-K., Kim, S. J., Kim, S.-J., Kwak, S., Oh, G., Kim, H., Yoo, H. J., et al. (2016) · Organogenesis · doi:10.1080/15476278.2016.1172164 · Cited by 50
“In humans, ELOVL1 knockdown lowers C26 fatty acid levels in Xlinked adrenoleukodystrophy (X-ALD) fibroblasts by reducing the elongation of C22 fatty acids to C26, which highlights the therapeutic potential of ELOVL1 modulation for the treatment of X-ALD.(14) Elovl1 is highly expressed in the stomach, lung, kidney, ski…”
BackgroundInfluentialZhang, X., De Marcos Lousa, C., Schutte-Lensink, N., Ofman, R., Wanders, R. J., Baldwin, S. A., Baker, A., Kemp, S., & Theodoulou, F. L. (2011) · Biochemical Journal · doi:10.1042/bj20110249 · Cited by 43
“Increased levels of VLCFA-CoA in X-ALD fibroblasts [15] and complementation of the yeast pxa1 pxa2 mutant by human ABCD1 [16] provided evidence that ALDP is also able to transport very long chain FA-CoA.”
BackgroundSelf-citationHama, K., Fujiwara, Y., Hayama, T., Ozawa, T., Nozawa, K., Matsuda, K., Hashiguchi, Y., & Yokoyama, K. (2021) · Scientific Reports · doi:10.1038/s41598-021-85603-w · Cited by 46
Lipidomic biomarkers in plasma correlate with disease severity in adrenoleukodystrophy
Jaspers, Y. R. J., Yska, H. A. F., Bergner, C. G., Dijkstra, I. M. E., Huffnagel, I. C., Voermans, M. M. C., Wever, E. J. M., Salomons, G. S., Vaz, F. M., Jongejan, A., et al. (2024) · Communications Medicine · doi:10.1038/s43856-024-00605-9 · Cited by 50
“These include the availability of fatty acids for VLCFA synthesis, the rate of VLCFA synthesis, residual ABCD1-mediated peroxisomal membrane translocation capacity, peroxisomal β --oxidation, and VLCFA elongation to longer species by ELOVL1 50 .”
BackgroundSelf-citationEnzymatic characterization of ELOVL1, a key enzyme in very long-chain fatty acid synthesis
Schackmann, M. J. A., Ofman, R., Dijkstra, I. M. E., Wanders, R. J. A., & Kemp, S. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2014.12.005 · Cited by 43
“Previously, we identified ELOVL1 as the elongase responsible for the elongation of C22:0 to C24:0 and C26:0 [12] and demonstrated that knockdown of ELOVL1 lowers C26:0 synthesis and C26:0 levels in X-ALD fibroblasts [12], which provided proof-of-concept for”
BackgroundMethodSelf-citationMetabolic rerouting via SCD1 induction impacts X-linked adrenoleukodystrophy
Raas, Q., van de Beek, M.-C., Forss-Petter, S., Dijkstra, I. M. E., Deschiffart, A., Freshner, B. C., Stevenson, T. J., Jaspers, Y. R. J., Nagtzaam, L., Wanders, R. J. A., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci142500 · Cited by 40
“To investigate the pathway underlying the elevated levels of C26:0, we had previously developed a method to measure de novo D3-C26:0 synthesis in whole cells using 3 days of treatment with deuterium-labeled LCFA C16:0 (D3-C16:0) (20).”
BackgroundMethodSelf-citationMuneer, Z., Wiesinger, C., Voigtländer, T., Werner, H. B., Berger, J., & Forss-Petter, S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0108655 · Cited by 33
Junjvlieke, Z., Mei, C., Khan, R., Zhang, W., Hong, J., Wang, L., Li, S., & Zan, L. (2019) · Journal of Cellular Biochemistry · doi:10.1002/jcb.28667 · Cited by 41
Rodríguez-Pascau, L., Vilalta, A., Cerrada, M., Traver, E., Forss-Petter, S., Weinhofer, I., Bauer, J., Kemp, S., Pina, G., Pascual, S., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abc0555 · Cited by 40
Self-citationFunctional Characterization of IPSC-Derived Brain Cells as a Model for X-Linked Adrenoleukodystrophy
Baarine, M., Khan, M., Singh, A., & Singh, I. (2015) · PLOS ONE · doi:10.1371/journal.pone.0143238 · Cited by 38
“Recent studies [15,16] suggest that in addition to deficient catabolism as a result of loss of ABCD1 function [9,10,17], the synthesis of VLCFA by ELOVL1may contribute to cell specific accumulation of VLCFA [16,18].”
BackgroundPrognostic value of fatty acid metabolism-related genes in patients with hepatocellular carcinoma
He, D., Cai, L., Huang, W., Weng, Q.-Q., Lin, X., You, M., & Liao, S. (2021) · Aging · doi:10.18632/aging.203288 · Cited by 46
“In addition, elongation of very-long-chain fatty acids 1 (ELOVL1) is a single elongase catalyzing the synthesis of both saturated very-long-chain fatty acids (VLCFAs) and monounsaturated VLCFAs [26].”
BackgroundSingh, J., Khan, M., & Singh, I. (2011) · Journal of Lipid Research · doi:10.1194/jlr.m017491 · Cited by 37
Matsumori, R., Miyazaki, T., Shimada, K., Kume, A., Kitamura, Y., Oshida, K., Yanagisawa, N., Kiyanagi, T., Hiki, M., Fukao, K., et al. (2012) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.10.025 · Cited by 42
Saturated very long-chain fatty acids regulate macrophage plasticity and invasiveness
Zierfuss, B., Buda, A., Villoria-González, A., Logist, M., Fabjan, J., Parzer, P., Battin, C., Vandersteene, S., Dijkstra, I. M. E., Waidhofer-Söllner, P., et al. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02664-y · Cited by 34
“This was accompanied by significant downregulation of ELOVL1, encoding the enzyme involved in saturated VLCFA synthesis [41] (Fig.”
BackgroundSelf-citationWang, X.-M., Yik, W. Y., Zhang, P., Lu, W., Dranchak, P. K., Shibata, D., Steinberg, S. J., & Hacia, J. G. (2012) · Stem Cell Research & Therapy · doi:10.1186/scrt130 · Cited by 33
“VLCFA levels are determined by their rate of synthesis (that is, catalyzed by fatty acid elongating enzyme ELOVL1 [79]), degradation (affected by ABCD1 and ABCD2 function [80]) and uptake of these fatty acids from the culture medium.”
BackgroundInfluentialDarwisch, W., von Spangenberg, M., Lehmann, J., Singin, Ö., Deubert, G., Kühl, S., Roos, J., Horstmann, H., Körber, C., Hoppe, S., et al. (2020) · Communications Biology · doi:10.1038/s42003-020-01442-x · Cited by 32
Terluk, M. R., Tieu, J., Sahasrabudhe, S. A., Moser, A. B., Watkins, P. A., Raymond, G. V., & Kartha, R. V. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01226-7 · Cited by 39
Peroxisomes and their central role in metabolic interaction networks in humans.
Wanders, R. J. A., Waterham, H. R., & Ferdinandusse, S. (2018) · Subcellular Biochemistry · doi:10.1007/978-981-13-2233-4_15 · Cited by 31
Self-citationMyelin lesions associated with lysosomal and peroxisomal disorders
Faust, P. L., Kaye, E. M., & Powers, J. M. (2010) · Expert Review of Neurotherapeutics · doi:10.1586/ern.10.127 · Cited by 33
Bezafibrate for X-Linked Adrenoleukodystrophy
Engelen, M., Tran, L., Ofman, R., Brennecke, J., Moser, A. B., Dijkstra, I. M. E., Wanders, R. J. A., Poll-The, B. T., & Kemp, S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0041013 · Cited by 30
“. We identified ELOVL1 as the enzyme responsible for the synthesis of VLCFA”
BackgroundSelf-citationXi, Y., Lindenmayer, L., Kline, I., von Einem, J., & Purdy, J. G. (2021) · mBio · doi:10.1128/mbio.00167-21 · Cited by 30
Richmond, P. A., van der Kloet, F., Vaz, F. M., Lin, D., Uzozie, A., Graham, E., Kobor, M., Mostafavi, S., Moerland, P. D., Lange, P. F., et al. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00520 · Cited by 29
Self-citationLogan, S., Agbaga, M.-P., Chan, M. D., Brush, R. S., & Anderson, R. E. (2014) · Journal of Lipid Research · doi:10.1194/jlr.m045443 · Cited by 28
Alterations of Ultra Long-Chain Fatty Acids in Hereditary Skin Diseases—Review Article
Zwara, A., Wertheim-Tysarowska, K., & Mika, A. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.730855 · Cited by 26
Wanders, R. J. A., Vaz, F. M., Ferdinandusse, S., Kuilenburg, A. B. P., Kemp, S., van Karnebeek, C., Waterham, H. R., & Houtkooper, R. H. (2019) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12008 · Cited by 28
Self-citationvan Engen, C. E., Ofman, R., Dijkstra, I. M. E., van Goethem, T. J., Verheij, E., Varin, J., Vidaud, M., Wanders, R. J. A., Aubourg, P., Kemp, S., et al. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2016.07.006 · Cited by 26
Self-citationDeciphering the modifiers for phenotypic variability of X-linked adrenoleukodystrophy
Palakuzhiyil, S. V., Christopher, R., & Chandra, S. R. (2020) · World Journal of Biological Chemistry · doi:10.4331/wjbc.v11.i3.99 · Cited by 24
Singh, J., Khan, M., Pujol, A., Baarine, M., & Singh, I. (2013) · PLoS ONE · doi:10.1371/journal.pone.0070712 · Cited by 24
Singh, J., Olle, B., Suhail, H., Felicella, M. M., & Giri, S. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13562 · Cited by 24
“ALDP deficiency impairs VLCFA b-oxidation activity and the resultant accumulation of VLCFA (C26 : 0) (Ofman et al. 2010).”
BackgroundTherapeutic strategies in adrenoleukodystrophy
Turk, B. R., Moser, A. B., & Fatemi, A. S. (2017) · Wiener Medizinische Wochenschrift · doi:10.1007/s10354-016-0534-2 · Cited by 26
Mah, M.-Q., Kuah, M., Ting, S. Y., Merosha, P., Janaranjani, M., Goh, P.-T., Jaya-Ram, A., & Shu‐Chien, A. C. (2019) · Comparative Biochemistry and Physiology Part B Biochemistry and Molecular Biology · doi:10.1016/j.cbpb.2019.01.011 · Cited by 23
Kawaguchi, K., Mukai, E., Watanabe, S., Yamashita, A., Morita, M., So, T., & Imanaka, T. (2021) · Scientific Reports · doi:10.1038/s41598-021-81949-3 · Cited by 25
Wang, X. M., Yik, W. Y., Zhang, P., Lu, W., Huang, N., Kim, B. R., Shibata, D. K., Zitting, M., Chow, R. H.-P., Moser, A. B., et al. (2015) · Stem Cell Research & Therapy · doi:10.1186/s13287-015-0149-3 · Cited by 24
“agreement with our prior report [20], the pivotal ELOVL1 family member responsible for the elongation of C22:0 to C24:0 and C26:0 fatty acids [71, 72] had significantly higher expression in fibroblasts relative to iPSCs, regardless of donor health status.”
ResultTheodoulou, F. L., Carrier, D. J., Schaedler, T. A., Baldwin, S. A., & Baker, A. (2016) · Biochemical Society Transactions · doi:10.1042/bst20160040 · Cited by 22
Profiling and Imaging of Phospholipids in Brains of Abcd1‐Deficient Mice
Hama, K., Fujiwara, Y., Morita, M., Yamazaki, F., Nakashima, Y., Takei, S., Takashima, S., Setou, M., Shimozawa, N., Imanaka, T., et al. (2018) · Lipids · doi:10.1002/lipd.12022 · Cited by 24
Singh, J., Khan, M., & Singh, I. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2013.01.004 · Cited by 21
“The VLCFA which accumulate in X-ALD are partly absorbed from the diet [47], but mostly result from endogenous synthesis through elongation of long chain fatty acids [4].”
BackgroundInfluentialShi, Y., Sun, X.-C., Sun, Y., Hou, L., Yao, M., Lian, K., Li, J., Lu, X., & Jiang, L. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.11.067 · Cited by 22
“Inhibition of ELOVL1 is reported to lower the level of C22:0, C24:0 (Sassa et al., 2014) and C26:0 (Ofman et al., 2010).”
Background(2006) · Springer eBooks · doi:10.1007/3-540-29623-9_9160 · Cited by 21
Weinhofer, I., Buda, A., Kunze, M., Palfi, Z., Traunfellner, M., Hesse, S., Villoria-Gonzalez, A., Hofmann, J., Hametner, S., Regelsberger, G., et al. (2022) · Communications Biology · doi:10.1038/s42003-022-03867-y · Cited by 20
Self-citationPretto, S., Yu, Q., Bourdely, P., Cafarello, S. T., Acker, H. H. V., Verelst, J., Richiardone, E., Vanheer, L., Roshanzadeh, A., Schneppenheim, F., et al. (2025) · Nature Metabolism · doi:10.1038/s42255-025-01233-w · Cited by 26
“Elovl1 has been widely studied in brain diseases such as adre-noleukodystrophy and certain tumour types as an unfavourable prognostic marker 56–58 .”
Discovery of Novel, Orally Bioavailable Pyrimidine Ether-Based Inhibitors of ELOVL1
Boyd, M. J., Collier, P. N., Clark, M. P., Deng, H., Kesavan, S., Ronkin, S. M., Waal, N. D., Wang, J., Cao, J., Li, P., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00948 · Cited by 20
The pathology of X-linked adrenoleukodystrophy: Tissue specific changes as a clue to pathophysiology
Yska, H. A. F., Engelen, M., & Bugiani, M. (2024) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-024-03105-0 · Cited by 20
“The enzyme ELOVL1, which is located in the membrane of the endoplasmic reticulum, plays an important role in fatty acid elongation [75].”
BackgroundThe Impact of a Ketogenic Diet and Liver Dysfunction on Serum Very Long‐Chain Fatty Acids Levels
Stradomska, T. J., Bachański, M., Pawłowska, J., Syczewska, M., Stolarczyk, A., & Tylki‐Szymańska, A. (2013) · Lipids · doi:10.1007/s11745-013-3761-y · Cited by 20
“The detected level of C22:0 is a result of mainly biochemical pathways, elongation and b-oxidation, in which this fatty acid takes part as a substrate or product [18, 19].”
BackgroundTherapeutic Role of ELOVL in Neurological Diseases
Siddiqui, A. J., Jahan, S., Chaturvedi, S., Siddiqui, M. A., Alshahrani, M. M., Abdelgadir, A., Hamadou, W. S., Saxena, J., Sundararaj, B. K., Snoussi, M., et al. (2023) · ACS Omega · doi:10.1021/acsomega.3c00056 · Cited by 22
High hexacosanoic acid levels are associated with coronary artery disease
Miyazaki, T., Shimada, K., Hiki, M., Kume, A., Kitamura, Y., Oshida, K., Yanagisawa, N., Kiyanagi, T., Matsumori, R., & Daida, H. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.01.031 · Cited by 20
“In addition, the expression of enzymes involved in fatty acid synthesis and elongation may contribute to the accumulation of VLCFAs, such as the two specific elongase of VLCFAs 1and 3 (ELOVL1 and ELOVL3) [17,18].”
BackgroundEndocrine dysfunction in adrenoleukodystrophy
Engelen, M., Kemp, S., & Eichler, F. (2021) · Handbook of clinical neurology · doi:10.1016/b978-0-12-819973-2.00018-6 · Cited by 21
Self-citationZuo, W., Li, C., Luan, Y., Zhang, H., Tong, X., Han, M., Gao, R., Hu, H., Song, J., Dai, F., et al. (2018) · Genome · doi:10.1139/gen-2017-0224 · Cited by 20
Differential roles for ACBD4 and ACBD5 in peroxisome-ER interactions and lipid metabolism.
Costello, J. L., Koster, J., Silva, B. S. C., Worthy, H. L., Schrader, T. A., Hacker, C., Passmore, J., Kuypers, F. A., Waterham, H. R., & Schrader, M. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.105013 · Cited by 18
“A decreased D3-C16:0/D3C26:0 ratio likely reflects increased chain elongation of the deuterium labeled C22:0 substrate via the ELOVL pathway on the ER, due to impairment of the peroxisomal betaoxidation pathway (33).”
BackgroundDiscovery and Optimization of Pyrazole Amides as Inhibitors of ELOVL1
Come, J. H., Senter, T. J., Clark, M. P., Court, J. J., Gale-Day, Z. J., Gu, W., Krueger, E. B., Liang, J., Morris, M., Nanthakumar, S. S., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00944 · Cited by 17
Ferraz, R., Paixão, R. V., Lopes‐Marques, M., Machado, A. M., Salaro, A. L., Castro, L. F. C., Monroig, Ó., & de Almeida, F. L. (2022) · Comparative Biochemistry and Physiology Part B Biochemistry and Molecular Biology · doi:10.1016/j.cbpb.2022.110749 · Cited by 19
Metadata
- Authors
- Ofman, R., Dijkstra, I. M. E., van Roermund, C. W. T., Burger, N., Turkenburg, M., van Cruchten, A., van Engen, C. E., Wanders, R. J. A., & Kemp, S.
- Affiliations
- Amsterdam UMC Location University of Amsterdam (NL)
- Corresponding author
- Kemp, Stephan
- Venue
- EMBO Molecular Medicine
- Published
- 2010-02-17
- Volume
- 2
- Issue
- 3
- Pages
- 90-97
- ISSN
- 1757-4676 (ISSN-L)
- 1757-4684
- PMC
- PMC3377275
- OpenAlex
- W2111220794
- Cited by
- 170
- References
- 38
- Citations by year
- 2026: 11 · 2025: 6 · 2024: 14 · 2023: 8 · 2022: 8 · 2021: 20 · 2020: 11 · 2019: 8 · 2018: 10 · 2017: 5 · 2016: 13 · 2015: 9 · 2014: 12 · 2013: 11 · 2012: 10
- FWCI
- 6.83
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- EMBO Molecular Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- European Leukodystrophy Association (2006‐031I4, 2008‐001C4)
- Netherlands Organization for Scientific Research (016.086.328)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Lipid metabolism and biosynthesis
- Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
- Keywords
- X-linked adrenoleukodystrophy, ELOVL1, very long chain fatty acids, ABCD1, ALDP, peroxisomal beta-oxidation, fibroblasts, therapeutic target
- MeSH terms
- ATP Binding Cassette Transporter, Subfamily D, Member 1, Fatty Acid Elongases, Acetyltransferases, Adrenoleukodystrophy, Fatty Acids, Homeostasis, Humans, ATP-Binding Cassette Transporters, Peroxisomes, Gene Knockdown Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.